Table 4.
Patient-specific clinical factors associated with progression-free survival in the BRCA1/2 mutation-negative group (N = 61).
| Variable | N | No. of events | (%) | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|---|---|---|
| Crude HR (95% CI) | P-value | Adjusted HR (95% CI) | P-value | ||||
| PFI | |||||||
| ≥ 12 months | 31 | 22 | 71.0 | 0.49 (0.24–0.95) | 0.042 | 0.44 (0.20–0.89) | 0.027 |
| < 12 months | 30 | 20 | 66.7 | 1 | 1 | ||
| Response to the last platinum dose according to RECIST | |||||||
| Complete | 11 | 8 | 72.7 | 0.46 (0.11–1.29) | 0.202 | ||
| Partial | 50 | 34 | 68.0 | 1 | |||
| CA-125 level within reference values after the last platinum dose | |||||||
| ≤ 35 U/mL | 45 | 29 | 64.4 | 0.46 (0.24–0.95) | 0.028 | 0.42 (0.20–0.96) | 0.030 |
| > 35 U/mL | 16 | 13 | 81.3 | 1 | 1 | ||
| Age | |||||||
| ≥ 60 years | 35 | 27 | 77.1 | 0.84 (0.45–1.57) | 0.570 | ||
| < 60 years | 26 | 15 | 57.7 | 1 | |||
| NLR | |||||||
| ≥ 3.32 | 10 | 6 | 60.0 | 0.77 (0.23–1.94) | 0.623 | ||
| < 3.32 | 51 | 36 | 70.6 | 1 | |||
| PLR | |||||||
| ≥ 210 | 21 | 16 | 76.2 | 1.69 (0.85–3.26) | 0.123 | 3.05 (1.38–6.58) | 0.005 |
| < 210 | 40 | 26 | 65.0 | 1 | 1 | ||
BRCA breast cancer susceptibility gene, HR hazard ratio, CI confidence interval, PFI platinum-free interval, RECIST Response Evaluation Criteria in Solid Tumors, CA-125 cancer antigen 125, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio.